Suppr超能文献

CXCL1作为非小细胞肺癌中受DACH1负调控的不良预后因素

CXCL1 as an Unfavorable Prognosis Factor Negatively Regulated by DACH1 in Non-small Cell Lung Cancer.

作者信息

Yu Shengnan, Yi Ming, Xu Linping, Qin Shuang, Li Anping, Wu Kongming

机构信息

Department of Oncology, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.

Department of Medical Oncology, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China.

出版信息

Front Oncol. 2020 Jan 10;9:1515. doi: 10.3389/fonc.2019.01515. eCollection 2019.

Abstract

Interaction between cancer cells with microenvironment is essential for cancer progression, therapeutic resistance and prognosis. Chemokine CXCL1 shows variable roles in the development of cancers. DACH1 has been considered as a tumor suppressor and represses the expressions of several chemokines. The relationship between CXCL1 and DACH1 in non-small cell lung cancer (SCLC) deserves further investigation. Immunohistochemistry staining was performed on tumor tissue microarrays from lung cancer patients to detect CXCL1 protein. The CXCL1 concentration in the serum of adenocarcinoma patients was measured by ELISA. The CXCL1 protein secreted by cancer cell lines was detected by SearchLight proteome array and human cytokine antibody array. The meta-analysis of CXCL1 expression form public databases was performed and correlation between CXCL1 and DACH1 was analyzed. Moreover, the association between clinicopathological features and prognosis with CXCL1 and DACH1 was analyzed by tissue array and KM-plotter from public database. The protein abundance of CXCL1 in lung cancer tissues was significantly higher than that in adjacent normal tissues. CXCL1 was closely related to TNM stage, tumor size, and lymph node metastasis and predicted worse overall survival in adenocarcinoma. The level of CXCL1 in the peripheral blood of adenocarcinoma patients also significantly elevated and positively related with clinical stage. The meta-analysis demonstrated that CXCL1 mRNA level was increased in lung cancer tissues and high level of CXCL1 indicated tumor progression in lung adenocarcinoma. In addition, public database analyses showed that CXCL1 negatively correlated with DACH1. Stable overexpressing DACH1 in cultured lung cancer cells remarkably decreased CXCL1 protein. Moreover, ectopic expression of DACH1 significantly inhibited the expression of CXCL1, Ki67, and cyclin D1 in tumor tissues compared with A549 cells with empty vector. Survival analysis showed that high CXCL1 and low DACH1 indicated poor overall survival and progression-free survival. CXCL1 is closely associated with tumor progression and poor survival. DACH1 significantly inhibits the expression of CXCL1 and indicates good prognosis. Therefore, combined detection of CXCL1 and DACH1 could more precisely predict prognosis of lung adenocarcinoma.

摘要

癌细胞与微环境之间的相互作用对于癌症进展、治疗抗性和预后至关重要。趋化因子CXCL1在癌症发展中表现出多种作用。DACH1被认为是一种肿瘤抑制因子,可抑制多种趋化因子的表达。非小细胞肺癌(NSCLC)中CXCL1与DACH1之间的关系值得进一步研究。对肺癌患者的肿瘤组织微阵列进行免疫组织化学染色以检测CXCL1蛋白。通过酶联免疫吸附测定法(ELISA)测量腺癌患者血清中的CXCL1浓度。通过SearchLight蛋白质组阵列和人细胞因子抗体阵列检测癌细胞系分泌的CXCL1蛋白。对来自公共数据库的CXCL1表达进行荟萃分析,并分析CXCL1与DACH1之间的相关性。此外,通过组织阵列和来自公共数据库的KM-plotter分析CXCL1和DACH1与临床病理特征及预后之间的关联。肺癌组织中CXCL1的蛋白丰度显著高于相邻正常组织。CXCL1与TNM分期、肿瘤大小和淋巴结转移密切相关,并预示腺癌患者的总生存期较差。腺癌患者外周血中CXCL1水平也显著升高,且与临床分期呈正相关。荟萃分析表明,肺癌组织中CXCL1 mRNA水平升高,CXCL1高水平表明肺腺癌肿瘤进展。此外,公共数据库分析显示CXCL1与DACH1呈负相关。在培养的肺癌细胞中稳定过表达DACH1可显著降低CXCL1蛋白水平。此外,与空载体的A549细胞相比,DACH1的异位表达显著抑制肿瘤组织中CXCL1、Ki67和细胞周期蛋白D1的表达。生存分析表明,高CXCL1和低DACH1表明总生存期和无进展生存期较差。CXCL1与肿瘤进展和不良生存密切相关。DACH1显著抑制CXCL1的表达并预示良好的预后。因此,联合检测CXCL1和DACH1可以更准确地预测肺腺癌的预后。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9193/6966305/31360c94a2a7/fonc-09-01515-g0001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验